MiR-205 suppresses autophagy and enhances radiosensitivity of prostate cancer cells by targeting TP53INP1

European Review for Medical and Pharmacological Sciences

Volumn 20, Issue 1, 2016, Pages 92-100

  Wang, W ^a   Liu, J ^a   Wu, Q ^b  

^a HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b XINXIANG MEDICAL UNIVERSITY   (China)

Author keywords

Autophagy; miR 205; Prostate cancer; Radiosensitivity; TP53INP1

Indexed keywords

MICRORNA 205; PROTEIN P62; TUMOR PROTEIN; TUMOR PROTEIN P53 INDUCIBLE NUCLEAR PROTEIN 1; UNCLASSIFIED DRUG; CARRIER PROTEIN; HEAT SHOCK PROTEIN; MICRORNA; MIRN205 MICRORNA, HUMAN; TP53INP1 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CELL PROTECTION; CONTROLLED STUDY; ECTOPIC EXPRESSION; HUMAN; HUMAN CELL; IRRADIATION; LNCAP CELL LINE; MALE; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROSTATE EPITHELIUM CELL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN TARGETING; RADIOSENSITIVITY; WESTERN BLOTTING; GENE EXPRESSION; GENETICS; PROSTATE TUMOR; RADIATION TOLERANCE; TUMOR CELL LINE;

AUTOPHAGY; CARRIER PROTEINS; CELL LINE, TUMOR; GENE EXPRESSION; HEAT-SHOCK PROTEINS; HUMANS; MALE; MICRORNAS; PROSTATIC NEOPLASMS; RADIATION TOLERANCE;

EID: 84957932419     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. TAO ZQ, SHI AM, WANG KX, ZHANG WD. Epidemiology of prostate cancer: current status. Eur Rev Med Pharmacol Sci 2015; 19: 805-812.
2. ALBERTI C. Prostate cancer: radioresistance molecular target-related markers and foreseeable modalities of radiosensitization. Eur Rev Med Pharmacol Sci 2014; 18: 2275-2282.
3. CHANG L, GRAHAM PH, HAO J, BUCCI J, COZZI PJ, KEARSLEY JH, LI Y. Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy. Cancer Metastasis Rev 2014; 33: 469-496.
4. DEGENHARDT K, MATHEW R, BEAUDOIN B, BRAY K, ANDERSON D, CHEN G, MUKHERJEE C, SHI Y, GELINAS C, FAN Y, NELSON DA, JIN S, WHITE E. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 2006; 10: 51-64.
5. HUMBERT M, MEDOVA M, AEBERSOLD DM, BLAUKAT A, BLADT F, FEY MF, ZIMMER Y, TSCHAN MP. Protective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cells. Biochem Biophys Res Commun 2013; 431: 264-269.
6. CHAACHOUAY H, OHNESEIT P, TOULANY M, KEHLBACH R, MULTHOFF G, RODEMANN HP. Autophagy contributes to resistance of tumor cells to ionizing radiation. Radiother Oncol 2011; 99: 287-292.
7. WANG J, YANG K, ZHOU L, MINHAOWU, WU Y, ZHU M, LAI X, CHEN T, FENG L, LI M, HUANG C, ZHONG Q, HUANG X. MicroRNA-155 promotes autophagy to eliminate intracellular mycobacteria by targeting Rheb. PLoS Pathog 2013; 9: e1003697.
8. FRANKEL LB, WEN J, LEES M, HOYER-HANSEN M, FARKAS T, KROGH A, JAATTELA M, LUND AH. microRNA-101 is a potent inhibitor of autophagy. EMBO J 2011; 30: 4628-4641.
9. WANG Z, WANG N, LIU P, CHEN Q, SITU H, XIE T, ZHANG J, PENG C, LIN Y, CHEN J. MicroRNA-25 regulates chemoresistance-associated autophagy in breast cancer cells, a process modulated by the natural autophagy inducer isoliquiritigenin. Oncotarget 2014; 5: 7013-7026.
10. ZHANG X, SHI H, LIN S, BA M, CUI S. MicroRNA- 216a enhances the radiosensitivity of pancreatic cancer cells by inhibiting beclin-1-mediated autophagy. Oncol Rep 2015; 34: 1557-1564.
11. HAGMAN Z, HAFLIDADOTTIR BS, CEDER JA, LARNE O, BJARTELL A, LILJA H, EDSJO A, CEDER Y. miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients. Br J Cancer 2013; 108: 1668-1676.
12. WANG N, LI Q, FENG NH, CHENG G, GUAN ZL, WANG Y, QIN C, YIN CJ, HUA LX. miR-205 is frequently downregulated in prostate cancer and acts as a tumor suppressor by inhibiting tumor growth. Asian J Androl 2013; 15: 735-741.
13. PENNATI M, LOPERGOLO A, PROFUMO V, DE CESARE M, SBARRA S, VALDAGNI R, ZAFFARONI N, GANDELLINI P, FOLINI M. miR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells. Biochem Pharmacol 2014; 87: 579-597.
14. GIUSIANO S, GARCIA S, ANDRIEU C, DUSETTI NJ, BASTIDE C, GLEAVE M, TARANGER-CHARPIN C, IOVANNA JL, ROCCHI P. TP53INP1 overexpression in prostate cancer correlates with poor prognostic factors and is predictive of biological cancer relapse. Prostate 2012; 72: 117-128.
15. GIUSIANO S, BAYLOT V, ANDRIEU C, FAZLI L, GLEAVE M, IOVANNA JL, TARANGER-CHARPIN C, GARCIA S, ROCCHI P. TP53INP1 as new therapeutic target in castration- resistant prostate cancer. Prostate 2012; 72: 1286-1294.
16. SEILLIER M, PEUGET S, GAYET O, GAUTHIER C, N'GUESSAN P, MONTE M, CARRIER A, IOVANNA JL, DUSETTI NJ. TP53INP1, a tumor suppressor, interacts with LC3 and ATG8-family proteins through the LC3- interacting region (LIR) and promotes autophagydependent cell death. Cell Death Differ 2012; 19: 1525-1535.
17. SAADI H, SEILLIER M, CARRIER A. The stress protein TP53INP1 plays a tumor suppressive role by regulating metabolic homeostasis. Biochimie 2015.
18. CHANG Y, YAN W, HE X, ZHANG L, LI C, HUANG H, NACE G, GELLER DA, LIN J, TSUNG A. miR-375 inhibits autophagy and reduces viability of hepatocellular carcinoma cells under hypoxic conditions. Gastroenterology 2012; 143: 177-187 e178.
19. BRISTOL ML, DI X, BECKMAN MJ, WILSON EN, HENDERSON SC, MAITI A, FAN Z, GEWIRTZ DA. Dual functions of autophagy in the response of breast tumor cells to radiation: cytoprotective autophagy with radiation alone and cytotoxic autophagy in radiosensitization by Vitamin D 3. Autophagy 2012; 8: 739-753.
20. YANG Y, YANG Y, YANG X, ZHU H, GUO Q, CHEN X, ZHANG H, CHENG H, SUN X. Autophagy and its function in radiosensitivity. Tumour Biol 2015; 36: 4079-4087.
21. YAMAMOTO A, TAGAWA Y, YOSHIMORI T, MORIYAMA Y, MASAKI R, TASHIRO Y. Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct Funct 1998; 23: 33-42.
22. SANCHO A, DURAN J, GARCIA-ESPANA A, MAUVEZIN C, ALEMU EA, LAMARK T, MACIAS MJ, DESALLE R, ROYO M, SALA D, CHICOTE JU, PALACIN M, JOHANSEN T, ZORZANO A. DOR/Tp53inp2 and Tp53inp1 constitute a metazoan gene family encoding dual regulators of autophagy and transcription. PLoS One 2012; 7: e34034.
23. GANDELLINI P, FOLINI M, LONGONI N, PENNATI M, BINDA M, COLECCHIA M, SALVIONI R, SUPINO R, MORETTI R, LIMONTA P, VALDAGNI R, DAIDONE MG, ZAFFARONI N. miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res 2009; 69: 2287-2295.
24. GANDELLINI P, PROFUMO V, CASAMICHELE A, FENDERICO N, BORRELLI S, PETROVICH G, SANTILLI G, CALLARI M, COLECCHIA M, POZZI S, DE CESARE M, FOLINI M, VALDAGNI R, MANTOVANI R, ZAFFARONI N. miR-205 regulates basement membrane deposition in human prostate: implications for cancer development. Cell Death Differ 2012; 19: 1750-1760.
25. PUHR M, HOEFER J, SCHAFER G, ERB HH, OH SJ, KLOCKER H, HEIDEGGER I, NEUWIRT H, CULIG Z. Epithelial- to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am J Pathol 2012; 181: 2188-2201.
26. QU C, LIANG Z, HUANG J, ZHAO R, SU C, WANG S, WANG X, ZHANG R, LEE MH, YANG H. MiR-205 determines the radioresistance of human nasopharyngeal carcinoma by directly targeting PTEN. Cell Cycle 2012; 11: 785-796.
27. ZHANG P, WANG L, RODRIGUEZ-AGUAYO C, YUAN Y, DEBEB BG, CHEN D, SUN Y, YOU MJ, LIU Y, DEAN DC, WOODWARD WA, LIANG H, YANG X, LOPEZBERESTEIN G, SOOD AK, HU Y, ANG KK, CHEN J, MA L. miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13. Nat Commun 2014; 5: 5671.
28. Carew JS, Kelly KR, Nawrocki ST. Autophagy as a target for cancer therapy: new developments. Cancer Manag Res 2012; 4: 357-365.
29. SUN Q, LIU T, YUAN Y, GUO Z, XIE G, DU S, LIN X, XU Z, LIU M, WANG W, YUAN Q, CHEN L. MiR-200c inhibits autophagy and enhances radiosensitivity in breast cancer cells by targeting UBQLN1. Int J Cancer 2015; 136: 1003-1012.
30. LIU Z, HUANG S. Inhibition of miR-191 contributes to radiation-resistance of two lung cancer cell lines by altering autophagy activity. Cancer Cell Int 2015; 15: 16.
31. ZOU Z, ZHANG J, ZHANG H, LIU H, LI Z, CHENG D, CHEN J, LIU L, NI M, ZHANG Y, YAO J, ZHOU J, FU J, LIANG Y. 3-Methyladenine can depress drug efflux transporters via blocking the PI3K-AKTmTOR pathway thus sensitizing MDR cancer to chemotherapy. J Drug Target 2014; 22: 839-848.
32. ITO S, KOSHIKAWA N, MOCHIZUKI S, TAKENAGA K. 3- Methyladenine suppresses cell migration and invasion of HT1080 fibrosarcoma cells through inhibiting phosphoinositide 3-kinases independently of autophagy inhibition. Int J Oncol 2007; 31: 261-268.
33. BOLL K, REICHE K, KASACK K, MORBT N, KRETZSCHMAR AK, TOMM JM, VERHAEGH G, SCHALKEN J, VON BERGEN M, HORN F, HACKERMULLER J. MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene 2013; 32: 277-285.
34. SEUX M, PEUGET S, MONTERO MP, SIRET C, RIGOT V, CLERC P, GIGOUX V, PELLEGRINO E, POUYET L, N'GUESSAN P, GARCIA S, DUFRESNE M, IOVANNA JL, CARRIER A, ANDRE F, DUSETTI NJ. TP53INP1 decreases pancreatic cancer cell migration by regulating SPARC expression. Oncogene 2011; 30: 3049-3061.